Texas Biomed and partners licensing new SARS-CoV-2 antibody targeting newest strains of COVID-19 SAN ANTONIO, May 30, 2024 /PRNewswire/ — SARS-CoV-2, the virus that causes COVID-19 disease, continues to evolve and evade current vaccine and therapeutic interventions. A consortium of…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.